Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System.

Ippazio Cosimo AntonazzoElisabetta PoluzziEmanuele ForcesiTrond RiiseKjetil BjornevikElisa BaldinLuigi MuratoriFabrizio De PontiEmanuel Raschi

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2018)

These real-world pharmacovigilance findings suggest that DILI might be a common feature of MS drugs and call for (1) formal population-based study to verify the risk of fampridine and (2) awareness by clinicians, who should assess the possible responsibility of MS drugs when they diagnose DILI.

Keyphrases

drug induced
liver injury
multiple sclerosis
adverse drug
mass spectrometry
ms ms
machine learning
white matter
palliative care
emergency department